DS
TCRX icon

David Shaw’s TScan Therapeutics TCRX Stock Holding History

David Shaw’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$537K Buy
548,402
+228,815
+72% +$244K ﹤0.01% 4153
2026
Q1 		$323K Buy
319,587
+250,160
+360% +$267K ﹤0.01% 4048
2025
Q4 		$69.4K Buy
+69,427
New +$100K ﹤0.01% 4419

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

David Shaw's TCRX Position: Q2 2026 in Review

David Shaw increased its TScan Therapeutics (TCRX) stake by 72% in Q2 2026, buying an estimated $244K and bringing the position to 548,402 shares worth $537K. The position accounts for ﹤0.01% of the portfolio, ranked #4153.

David Shaw first reported a position in TCRX in Q4 2025 and has held it in 3 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • David Shaw held 548,402 shares of TScan Therapeutics worth $537K as of Q2 2026.
  • David Shaw bought 228,815 TScan Therapeutics shares in Q2 2026, an estimated $244K.
  • TScan Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4153 holding.
  • David Shaw first reported a position in TScan Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.